P
Paul Golumbek
Researcher at Johns Hopkins University
Publications - 12
Citations - 6269
Paul Golumbek is an academic researcher from Johns Hopkins University. The author has contributed to research in topics: Immune system & Antigen. The author has an hindex of 9, co-authored 12 publications receiving 6186 citations.
Papers
More filters
Journal ArticleDOI
Vaccination with Irradiated Tumor Cells Engineered to Secrete Murine Granulocyte-Macrophage Colony-Stimulating Factor Stimulates Potent, Specific, and Long-Lasting Anti-Tumor Immunity
Glenn Dranoff,Elizabeth M. Jaffee,Audrey J. Lazenby,Paul Golumbek,Hyam I. Levitsky,Katja Brose,Valerie Jackson,Hirofumi Hamada,Drew M. Pardoll,Richard C. Mulligan +9 more
TL;DR: The results have important implications for the clinical use of genetically modified tumor cells as therapeutic cancer vaccines and the levels of anti-tumor immunity reported previously in cytokine gene transfer studies involving live, transduced cells could be achieved through the use of irradiated cells alone.
Journal ArticleDOI
Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens
Alex Yee-Chen Huang,Paul Golumbek,Mojgan Ahmadzadeh,Elizabeth M. Jaffee,Drew M. Pardoll,Hyam I. Levitsky +5 more
TL;DR: MHC class I-restricted antigens are efficiently transferred in vivo to bone marrow-derived antigen-presenting cells, which suggests that human leukocyte antigen matching may be less critical in the application of tumor vaccines than previously thought.
Journal ArticleDOI
Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response
Eric R. Fearon,Drew M. Pardoll,Toshiuki Itaya,Paul Golumbek,Hyam I. Levitsky,Jonathan W. Simons,Hajime Karasuyama,Bert Vogelstein,Philip Frost +8 more
TL;DR: These findings demonstrate that the failure of an effective antitumor immune response may be primarily due to a helper arm deficiency of the immune system rather than a paucity of tumor-specific cytotoxic effector cells and outline a novel strategy for augmenting tumor immunity.
Journal ArticleDOI
Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4
Paul Golumbek,Audrey J. Lazenby,Hyam I. Levitsky,Liz M. Jaffee,Hajime Karasuyama,Mitzi Baker,Drew M. Pardoll +6 more
TL;DR: Established parental tumors could be cured by the systemic immune response generated by injection of the genetically engineered tumors by providing a rationale for the use of lymphokine gene-transfected tumor cells as a modality for cancer therapy.
Journal Article
Controlled Release, Biodegradable Cytokine Depots: A New Approach in Cancer Vaccine Design
Paul Golumbek,Rosa Azhari,Elizabeth M. Jaffee,Hyam I. Levitsky,Audrey J. Lazenby,Kam W. Leong,Drew M. Pardoll +6 more
TL;DR: This work explored an alternate approach to generating sustained release of cytokines local to the tumor cells and resulted in systemic anti-tumor immune responses comparable to granulocyte-macrophage colony-stimulating factor gene transduced tumor vaccines.